Oncology Venture


SEK307.9m market cap

SEK4.08 last close

Oncology Venture is a biopharmaceutical company with a patent-protected mRNA-based drug response predictor platform that identifies patients highly likely to respond to treatment. The company is entering Phase II with six in-licensed drugs.

Investment summary

Oncology Venture holds the worldwide drug development rights to the drug response predictor (DRP), a microarray technology that examines the expression of a panel of genes to identify potential responders to different cancer therapies. The company’s goal is to then identify and in-license drugs that are active within populations that the DRP can identify. To date, the company has in-licensed six drugs and is in the early stages of validating the platform in the clinic.

Y/E Dec
Revenue (DKKm)
EPS (ore)
P/E (x)
P/CF (x)
2017A 5.1 (23.8) (31.0) (127.00) N/A N/A
2018A 2.1 (32.3) (22.5) (44.00) N/A N/A
2019E 3.6 (206.8) (208.6) (387.31) N/A N/A
2020E 3.6 (92.5) (92.5) (163.48) N/A N/A
Last updated on 22/05/2019
Industry outlook

Oncology Venture and the DRP system have the potential to identify the value in drug assets that have otherwise been discontinued by identifying patient populations where these drugs are active. This allows the company to in-license these assets at low cost, which the company may then out-license after clinical validation.

Last updated on 22/05/2019
Share price graph
Balance sheet
Forecast net debt (DKKm) 230
Forecast gearing ratio (%) 953
Price performance
Actual (18.4) (24.8) (49.3)
Relative* (16.2) (26.0) (50.0)
52-week high/low SEK12.7/SEK3.6
*% relative to local index
Key management
Peter Buhl Jensen CEO
Ulla Hald Buhl Chief Operating Officer